Physical activity in patients with sickle cell disease

Physical activity in patients with sickle cell disease: Effect on the vascular function, frequency of painful episodes and clinical course of the disease - drePAnon

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042826

Enrollment

Registered

2020-12-23

Start date

2020-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sickle cell disease

Interventions

Increase in the daily step-count by 25% compared to baseline, during the 2-month intervention period. Increase in the daily step-count by 25% compared to baseline during one month of the intervention,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - patients with confirmed sickle cell disease. - willing to participate to the study (written informed consent).

Exclusion criteria

Exclusion criteria: - no transfusion for the 2 months proceeding the study. - no vaso-occlusive crisis or acute chest syndrome for the 3 months preceding the study. - absence of leg ulcer, osteonecrosis of the femoral head. - absence of any condition impairing walking gait. Patients presenting a median daily step-count over 9000 or an average daily step-count over 10.000 at the end of the baseline period are not allocated to one of the trial arms. Their baseline data will be treated in a cross-sectional analysis.

Design outcomes

Primary

Measure	Time frame
- physical activity parameters (step-count, physical activity intensity), assessed daily and objectively using an activity tracker. - pain, assessed every day using a pain diary. - vaso-occlusive events and associated clinical signs. These primary outcomes are assessed on a minimum experimental period of 30 days.	—

Secondary

Measure	Time frame
- level of physical activity, using questionnaires. - quality of life, using questionnaires. - walking speed. - cardio-vascular function (pulse wave velocity, hear rate variability). - hematological parameters. - biochemistry parameters. - inflammation parameters (cytokines, vascular adhesion molecules, micro-particles). - hemorheological parameters (blood and plasma viscosities). - sleep quality (assessed every day using an activity tracker). These secondary outcomes are assessed at the beginning or at the end of each 30-day experimental period (unless specified otherwise in the above).	—

Measure

Time frame

- level of physical activity, using questionnaires. - quality of life, using questionnaires. - walking speed. - cardio-vascular function (pulse wave velocity, hear rate variability). - hematological parameters. - biochemistry parameters. - inflammation parameters (cytokines, vascular adhesion molecules, micro-particles). - hemorheological parameters (blood and plasma viscosities). - sleep quality (assessed every day using an activity tracker). These secondary outcomes are assessed at the beginning or at the end of each 30-day experimental period (unless specified otherwise in the above).

—

Countries

Japan,Europe,Africa

Contacts

Public ContactJulien Tripette

Ochanomizu University Center for Interdisciplinary AI and Data Science

tripette.julien@ocha.ac.jp0339433151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026